{{Incomplete|date=May 2016}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 449351504
| IUPAC_name = methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-[(4''R'',6''R'',8''S'')- 4-(1,1-difluoroethyl)- 8-(methoxycarbonyl)- 1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-''b'']indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate
| image = Vinflunine.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|vinflunine}}
| licence_EU = Javlor
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 162652-95-1
| ATC_prefix = L01
| ATC_suffix = CA05
| ATC_supplemental =  
|  PubChem = 10629256
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8804619
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5BF646324K
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 90241
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 510329

<!--Chemical data-->
| chemical_formula =  
| C=45 | H=54 | F=2 | N=4 | O=8 
| molecular_weight = 816.92 g/mol
| smiles = CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NMDYYWFGPIMTKO-KLCPSUAYSA-N

}}

'''Vinflunine''' ([[International Nonproprietary Name|INN]], trade name '''Javlor''') is a novel fluorinated [[Vinca alkaloid|''vinca'' alkaloid]] derivative<ref>{{cite journal|last1 = Kruczynski|first1 = Anna|last2 = Barret|first2 = Jean-Marc|last3 = Etiévant|first3 = Chantal|last4 = Colpaert|first4 = Francis|last5 = Fahy|first5 = Jacques|last6 = Hill|first6 = Bridget T.|title = Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated ''Vinca'' alkaloid|journal = [[Biochem. Pharmacol.]]|volume = 55|issue = 5|pages = 635–648|year = 1998|pmid = 9515574|doi = 10.1016/S0006-2952(97)00505-4}}</ref> undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University),<ref>{{cite journal|title = ''Vinca'' Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives|first1 = Jacques|last1 = Fahy|first2 = Alain|last2 = Duflos|first3 = Jean-Paul|last3 = Ribet|first4 = Jean-Claude|last4 = Jacquesy|first5 = Christian|last5 = Berrier|first6 = Marie-Paule|last6 = Jouannetaud|first7 = Fabien|last7 = Zunino|journal = [[J. Am. Chem. Soc.]]|year = 1997|volume = 119|issue = 36|pages = 8576–8577|doi = 10.1021/ja971864w}}</ref> developed by [[Laboratoires Pierre Fabre]] and was licensed to [[Bristol-Myers Squibb]] for development in certain countries, including the [[United States]].

On November 23, 2007, [[Pierre Fabre Medicament]] and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008."<ref>{{cite press release|url = http://newsroom.bms.com/article_display.cfm?article_id=5223|title = Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status|agency = [[Bristol-Myers Squibb]]|accessdate = June 27, 2008|date = November 23, 2007|dead-url = yes|archive-date = May 28, 2008|archive-url = https://web.archive.org/web/20080528000858/http://newsroom.bms.com:80/article_display.cfm?article_id=5223}}</ref>

{{as of|2016}}, vinflunine is the only commercially-approved agent in some countries for salvage therapy of [[urothelial carcinoma]], (with approval based on the results of a phase III trial), with a reported median [[overall survival|OS]] of about 6 months.<ref>{{cite journal|url = http://www.cancernetwork.com/oncology-journal/systemic-therapy-urothelial-carcinoma-renaissance-around-corner|title = Systemic Therapy for Urothelial Carcinoma: Is a Renaissance Around the Corner?|date = 2016|first = Guru|last = Sonpavde|journal = [[Oncology (Williston Park)]]|volume = 30|issue = 6|pages = 580–583, 588|pmid = 27306713 }}</ref><ref name = Bellmunt2009>{{cite journal|first1 = Joaquim|last1 = Bellmunt|first2 = Christine|last2 = Théodore|first3 = Tomasz|last3 = Demkov|first4 = Boris|last4 = Komyakov|first5 = Lisa|last5 = Sengelov|first6 = Gedske|last6 = Daugaard|first7 = Armelle|last7 = Caty|first8 = Joan|last8 = Carles|first9 = Agnieszka|last9 = Jagiello-Gruszfeld|first10 = Oleg|last10 = Karyakin|first11 = François-Michel|last11 = Delgado|first12 = Patrick|last12 = Hurteloup|first13 = Eric|last13 = Winquist|first14 = Nassim|last14 = Morsli|first15 = Yacine|last15 = Salhi|first16 = Stéphane|last16 = Culine|first17 = Hans|last17 = von der Maase|title = Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract|journal = [[J. Clin. Oncol.]]|year = 2009|pmid = 19687335|doi = 10.1200/JCO.2008.20.5534|volume = 27|issue = 27|pages = 4454–4461}}</ref>
 
==Approvals and indications==
{{as of|2012}}, vinflunine is registered for use in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen," but is not covered under the [[Pharmaceutical Benefits Scheme]].<ref>{{cite web|url = http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-vinflunine-nov11|work = [[Pharmaceutical Benefits Scheme]]|date = March 16, 2012|title = Vinflunine, solution concentration for I.V. infusion, 50 mg in 2 mL and 250 mg in 10 mL (as ditartrate), Javlor® – November 2011|accessdate = June 22, 2017}}</ref>
==Clinical trials==
It has undergone a phase III clinical trial for advanced [[transitional cell carcinoma]] of the urothelial tract.<ref name = Bellmunt2009 />

==References==
{{Reflist}}

{{Chemotherapeutic agents}}

[[Category:Mitotic inhibitors]]
[[Category:Alkaloids]]
[[Category:Bristol-Myers Squibb]]
[[Category:Acetate esters]]


{{antineoplastic-drug-stub}}